Juan Vera - Oct 31, 2025 Form 4 Insider Report for Marker Therapeutics, Inc. (MRKR)

Role: Chief Executive Officer, Director
Signature: /s/ Julio C. Esquivel as Attorney-In-Fact for Juan Vera
Stock symbol: MRKR
Transactions as of: Oct 31, 2025
Transactions value $: $0
Form type: 4
Date filed: 11/4/2025, 05:03 PM
Previous filing: Feb 14, 2025
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Vera Juan	Chief Executive Officer, Director	MARKER THERAPEUTICS, INC., 2450 HOLCOMBE BLVD, TMC PARTNERS OFFICE, HOUSTON	/s/ Julio C. Esquivel as Attorney-In-Fact for Juan Vera	2025-11-04	0001755495

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	MRKR	Employee Stock Option (right to buy)	Award	$0	+250K		$0.00	250K	Oct 31, 2025	Common Stock	250K	$0.99	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents options granted under the Company's 2020 Omnibus Stock Ownership Plan. One fourth of the shares vest on the first anniversary of the grant date and the remainder of the shares subsequently vest in equal annual installments over the second, third and fourth anniversary of the grant date upon the continued performance of services by the Reporting Person to the Company through the vesting dates. The option exercise price is the closing price on the date of the grant, October 31, 2025.

Content

Represents options granted under the Company's 2020 Omnibus Stock Ownership Plan. One fourth of the shares vest on the first anniversary of the grant date and the remainder of the shares subsequently vest in equal annual installments over the second, third and fourth anniversary of the grant date upon the continued performance of services by the Reporting Person to the Company through the vesting dates. The option exercise price is the closing price on the date of the grant, October 31, 2025.